Global CD Antigen Cancer Therapy Market Insights Forecasts to 2033

• The Global CD Antigen Cancer Therapy Market Size was Valued at USD 4.3 Billion in 2023
• The Market Size is Growing at a CAGR of 11.95% from 2023 to 2033
• The Worldwide CD Antigen Cancer Therapy Market Size is Expected to Reach USD 13.3 Billion by 2033
• Europe is Expected to Grow the fastest during the forecast period.

The Global CD Antigen Cancer Therapy Market Size is Anticipated to Exceed USD 13.3 Billion by 2033, Growing at a CAGR of 11.95% from 2023 to 2033. 

Market Overview

CD antigen cancer therapy occurs by targeting specific CD markers on cancer cells, allowing for greater accuracy treatment. Therapies such as CAR T-cells and monoclonal antibodies target tumours selectively by recognizing these cell membrane proteins, improving therapy efficacy while preventing harm to healthy cells. This method improves the accuracy and effectiveness of targeted cancer therapy. In addition, the CD antigen cancer therapy market is expanding rapidly, leading to the rising global cancer incidence and desire for targeted medicines. Discoveries in genetic engineering have resulted in the creation of innovative immunotherapies such as CAR T-cell treatments and antibody-drug conjugates that use the CD antigen as a target to eliminate cancer cells. The development of adapted medicine and the availability of genomic profiling resources are accelerating market growth. Additionally, Bristol Myers Squibb gained FDA approval in March 2024 for Breyanzi, a CD19-directed CART treatment, for adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma who have had at least two prior lines of therapy. Furthermore, government initiatives and alliances between pharmaceutical corporations and research institutions are promoting innovation and speeding up clinical trials, presenting significant opportunities for industry players. The ongoing research to discover additional CD markers and their applications across various cancer types is broadening the therapeutic scope of CD antigen-targeted therapies. This is likely to increase the market size by targeting more patient populations.

Report Coverage

This research report categorizes the global CD antigen cancer therapy market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global CD antigen cancer therapy market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global CD antigen cancer therapy market.

Driving Factors

CD antigen cancer therapeutics provide focused techniques that can improve treatment outcomes, contributing to higher acceptance and market growth. Biotechnology and genetic engineering improvements have aided the development of innovative CD antigen-targeted therapeutics, including antibody-drug conjugates (ADCs) and bispecific antibodies. These technological advancements boost the growth of the CD antigen cancer therapy market. Furthermore, governments and health authorities foster the discovery of innovative cancer treatments, which helps propel CD antigen cancer therapy market growth.

Restraining Factors

The accurate regulatory criteria of CD antigen cancer therapy hamper market expansion, and developing therapy, research, and tactics to target CD antigen cancer therapy takes time and money.

Market Segmentation

The global CD antigen cancer therapy market share is classified into therapy type, antigen type, cancer type, and end-user.

• The (CAR) T-cell therapy segment is expected to hold the largest share of the global CD antigen cancer therapy market during the forecast period.       

Based on therapy type, the global CD antigen cancer therapy market is categorized as monoclonal antibodies, (CAR) T-cell therapy, and bispecific antibodies. Among these, the (CAR) T-cell therapy segment is expected to hold the largest share of the global CD antigen cancer therapy market during the forecast period. CAR T-cell therapy is highly effective at targeting specific cancer cells, resulting in long-lasting responses in patients with certain forms of blood malignancies, such as leukaemia and lymphoma. Furthermore, continued advances in CAR T-cell therapy, such as improved cell engineering techniques and the development of new generations of CAR T-cells, are boosting treatment outcomes and broadening applications. Moreover, the expanding acceptance and application of CAR T-cell treatment in healthcare settings, as well as increased investment in CAR T-cell research, are significant drivers of its market dominance.

• The CD19 segment is expected to grow at the fastest CAGR during the forecast period.   

Based on the antigen type, the global CD antigen cancer therapy market is categorized as CD19, CD20, CD22, and CD30. Among these, the CD19 segment is expected to grow at the fastest CAGR during the forecast period. CD19 procedures, such as Kymriah and Yescarta, are driving market expansion due to their high success rate in treating B-cell malignancies including leukemia. Furthermore, recent approvals and expanded indications, as well as ongoing trials for novel medicines, have increased their uptake and accelerated segment growth.

• The leukaemia segment is expected to hold the largest share of the global CD antigen cancer therapy market during the forecast period.       

Based on cancer type, the global CD antigen cancer therapy market is categorized as leukaemia, lymphoma, multiple myeloma, and solid tumours. Among these, the leukaemia segment is expected to hold the largest share of the global CD antigen cancer therapy market during the forecast period. Leukemia, particularly B-cell malignancies such as acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL), accounts for an important number of cancer cases worldwide. The rising number of these tumours creates a demand for effective treatments. Moreover, continuous breakthroughs in CAR T-cell therapy and other immunotherapies improve the efficacy and safety of leukaemia treatments. As these technologies advance, healthcare providers are increasingly interested in investing in them.

• The therapeutic treatment segment is expected to grow at the fastest CAGR during the forecast period.   

Based on the end-user, the global CD antigen cancer therapy market is categorized as diagnostic testing, therapeutic treatment, research and development. Among these, the therapeutic treatment segment is expected to grow at the fastest CAGR during the forecast period. The invention of CD antigen-targeted medicines, such as CAR T-cell therapies, has led to increased treatment efficacy and patient survival rates, generating additional interest and funding for therapeutic approaches. Moreover, ongoing R&D activities aimed at improving existing medications and generating new treatments are promoting innovation and broadening the therapeutic options available to patients, boosting market growth.

Regional Segment Analysis of the Global CD Antigen Cancer Therapy Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is projected to hold the largest share of the global CD antigen cancer therapy market over the forecast period.

North America is projected to hold the largest share of the global CD antigen cancer therapy market over the forecast period. In North America, the CD antigen cancer therapy market is trending toward precision medicine and personalized oncology, with major expenditures in genomic profiling and targeted therapy development. Additionally, there is also a focus on collaborative research activities across academia, industry, and government organizations to encourage innovation and speed up medication discovery and development.

Europe is expected to grow at the fastest CAGR growth of the global CD antigen cancer therapy market during the forecast period.  In Europe, trends in the CD antigen cancer therapy market concentrate on regulatory harmonization and expedited approval processes to allow for quick access to novel treatments. There is also a stronger focus on cost-effectiveness and value-based healthcare models, which is driving the adoption of CD antigen therapies that show better clinical outcomes and cost reductions than standard treatments.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global CD antigen cancer therapy market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Altor BioScience
• Regeneron Pharmaceuticals
• Moderna, Inc.
• Kite Pharma
• Roche
• Adaptive Biotechnologies
• Cartesian Therapeutics
• Immatics
• Pfizer
• Magenta Therapeutics
• ADCT Therapeutics
• Cellectis
• Cytokinetics
• Gilead Sciences, Inc.
• Others

Key Market Developments

• In April 2023, Omisirge (omidubicel-onlv), an allogeneic cell treatment developed by Gamida Cell Ltd, was licensed by the US FDA for the treatment of hematologic malignancies in adults and children aged 12 and up.

• In April 2023, Genentech, a Roche Group firm, received FDA approval to utilize Polivy (polatuzumab vedotin-piiq) in combination with Rituxan (rituximab), cyclophosphamide, doxorubicin, and prednisone (R-CHP) as a cancer treatment drug. The medicine is used to treat adult patients with diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global CD antigen cancer therapy market based on the below-mentioned segments: 

Global CD Antigen Cancer Therapy Market, By Therapy Type

• Monoclonal Antibodies
• (CAR) T-cell Therapy
• Bispecific Antibodies

Global CD Antigen Cancer Therapy Market, By Antigen Type

• CD19
• CD20
• CD22
• CD30

Global CD Antigen Cancer Therapy Market, By Cancer Type

• Leukaemia
• Lymphoma
• Multiple Myeloma
• Solid Tumors

Global CD Antigen Cancer Therapy Market, By End-User

• Diagnostic Testing
• Therapeutic Treatment
• Research and Development

Global CD Antigen Cancer Therapy Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa